Pfizer set to merge off-patent drug business with Mylan

Pharmaceutical giants Pfizer and Mylan reached a deal today to combine the two companies off-patent generic drug businesses. The deal is expected to bring in $20 billion in annual sales next year. Yahoo Finance’s Alexis Christoforous, Brian Sozzi, and Anjalee Khemlani look further into the deal.